Journal: International Journal of Molecular Sciences
Article Title: Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus—Prone Mouse Model
doi: 10.3390/ijms26125809
Figure Lengend Snippet: Figure 2. Effects of in vivo rebamipide treatment on immune cell subsets and serologic phenotypes. (A,B) Immune cell subsets in splenocytes from 16-week-old mice treated with vehicle or rebamipide, analyzed by flow cytometry. (A) Percentages of double negative T (DNT, CD4−CD8−) cells, CD4+ T cells, T helper 1 (Th1, CD4+IFNg+) cells, regulatory T (Treg, CD4+CD25+Foxp3+) cells, CD8+ T cells, and T helper 2 (Th2, CD4+IL-4+) cells. (B) Percentages of plasma B cells (PC, CD19−CD138+) and IL- 10-producing B cells (B10, CD19+CD1d+CD5+IL-10+). (C) Serum levels of anti-dsDNA antibodies and immunoglobulin G2a (IgG2a) in the two groups of mice at 8, 12, and 16 weeks of age, determined by ELISA. Data are presented as medians with interquartile ranges. Statistical analyses were performed using the Mann–Whitney test (A,B) and two-way ANOVA (C). * p < 0.05.
Article Snippet: Collected sera from mice were assayed using the mouse anti-dsDNA IgG-specific ELISA kit (R&D systems) and anti-mouse immunoglobulin G2a (IgG2a) ELISA kit (Bethyl Laboratories, Montgomery, Tx, USA) according to the manufacturer’s instructions.
Techniques: In Vivo, Flow Cytometry, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY